Revolution Medicines Secures Powerhouse $2B Funding in Groundbreaking Royalty Pharma Deal
Revolution inks $2B flexible deal with Royalty Pharma to fund RAS(ON) inhibitors in cancer.
RAS-addicted cancers
Revolution inks $2B flexible deal with Royalty Pharma to fund RAS(ON) inhibitors in cancer.